Combination Therapy of Obicetrapib and Ezetimibe for Use in Statin Intolerant Patients Suffering from Hyperlipidemia or Mixed Dyslipidaemia
OwnerJohannes Jacob Pieter Kastelein, Marc Ditmarsch +1inventors
InventorsJohannes Jacob Pieter Kastelein, Marc Ditmarsch, Michael Harvey Davidson
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition and a therapeutic combination comprising obicetrapib and ezetimibe, which may be used in the treatment of subjects suffering from or having an increased risk for hyperlipidemia or mixed dyslipidemia and wherein said subjects are partially or completely intolerant to statins.
Claims19
1-34. (canceled)
A method of treating a subject suffering from or having an increased risk for hyperlipidemia or mixed dyslipidemia, the method comprising:
- administering to the subject a therapeutically effective amount of (i) obicetrapib, or a pharmaceutically acceptable salt or solvate thereof, and (ii) ezetimibe, or a pharmaceutically acceptable salt or solvate thereof,
- wherein the subject is partially or completely intolerant to statins.
A method of treating a subject suffering from cardiovascular disease or having an increased risk for cardiovascular disease, the method comprising:
- administering to the subject a therapeutically effective amount of (i) a CETP-inhibitor, or a pharmaceutically acceptable salt or solvate thereof, and (ii) ezetimibe, or a pharmaceutically acceptable salt of solvate thereof,
- wherein the subject is partially or completely statin intolerant.
A method for reducing the risk for cardiovascular events in a subject in need thereof, the method comprising:
- administering to the subject a therapeutically effective amount of (i) obicetrapib, or a pharmaceutically acceptable salt or solvate thereof, and (ii) ezetimibe, or a pharmaceutically acceptable salt or solvate thereof,
- wherein the subject is partially or completely statin intolerant.
Dependencies are inferred from the claim text.